SCHEMBL5470341

SCHEMBL5470341

COC(=O)C1=C(O)CCC(C#N)(c2cccc(OCc3ccccc3)c2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 3/20 0.45
MAOB P27338 2/20 0.45
NR4A2 P43354 1/20 0.41
SMPD1 P17405 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
GUSB P08236 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PTPN1 P18031 1/20 0.40
NR1H4 Q96RI1 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
GAA P10253 1/20 0.39
MAPK1 P28482 1/20 0.39
FAAH O00519 1/20 0.39
CNR2 P34972 1/20 0.39
HIF1A Q16665 1/20 0.39
ALOX5 P09917 1/20 0.39
SPHK2 Q9NRA0 1/20 0.39
SPHK1 Q9NYA1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4875995 0.86 KMT2A (0.51) ADAM17MEN1KMT2ALMNAHPGD
SCHEMBL3519738 0.80 OPRM1 (0.46) LMNAHPGD
SCHEMBL5465617 0.77 ALOX5 (0.52) ADAM17MAOBNR4A2SMPD1KMT2A
SCHEMBL12747704 0.74 MAOB (0.44) MAOBLMNAHPGDFAAH
SCHEMBL16462397 0.71 P2RX7 (0.34) MEN1KMT2ALMNA
SCHEMBL16463358 0.71 ALDH1A1 (0.34) MEN1KMT2ANR1H4LMNA
SCHEMBL16464410 0.71 VNN1 (0.33) LMNA
SCHEMBL10083334 0.70 MAOB (0.57) ADAM17MAOBNR4A2SMPD1KMT2A
SCHEMBL976424 0.69 MAOB (0.73) MAOBNR4A2SMPD1MRGPRX4MEN1
SCHEMBL30412034 0.69 MAOB (0.73) MAOBNR4A2SMPD1MRGPRX4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070078120-A1 Novel piperidine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-05 US disclosed
EP-1679069-A1 NOVEL PIPERIDINE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078120-A1 Novel piperidine derivative LDLR, PRMT5, MSR1 ADAM17 3517/4885MAOB 4021/4885NR4A2 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.